This could provide clinically useful insights into the impact of S100A12 on Pseudomonas as it might have the potential for use as a therapeutic intervention in addition to antibiotics to combat future infections and serve as a useful biomarker of pulmonary injuries in clinical diagnoses of sepsis-induced ARDS [55]. This evidence concerns the gene S100A12 and Sepsis.